Home
overview
The highly competitive market in today’s world has exacerbated the interest and importance of drug delivery issues. Staying abreast of the latest scientific, economic, and social benefits that can be derived from drug delivery systems can be both time consuming and costly. At SMi we have the solution. Drug Delivery 2001 – Next Generation Technology offers you the easy way to keep up to date in the latest Drug Delivery advancements, enabling you to lead the race in the production of drug delivery technology.

This is your opportunity to meet with key industry figures and seek their advice and opinions. Our in-depth programme will embrace the most important issues within drug delivery and will provide a forum to learn from first hand case studies and discuss the hot topics that everyone is talking about.

But that’s not all. With presentations from key industry players such as Pfizer, GlaxoSmithKline, AstraZeneca and Merck, alongside leading drug delivery companies Elan Pharmaceutical Technologies and Profile Therapeutics, you can be confident of gaining insight from the experts.

As a busy professional operating in this developing field, you will understand the importance of reviewing the latest technological developments and opportunities facing this ever-expanding market. Let SMi make this easier for you. SMi’s Drug Delivery 2001 – Next Generation Technology event is a time and labour saving way to ensure that you are up to date with the latest developments before your competitors are.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof Bob Davis

Prof Bob Davis, Lord Trent Professor of Pharmacy, Nottingham University

9:00 THE VALUE OF DRUG DELIVERY

Dr Richard Green

Dr Richard Green, Drug Delivery Evaluation, Pfizer

  • Industry overview
  • The market place and its players
  • Selection of technologies
  • Strategies for successful alliances
  • Licensing issues
  • Innovations in major delivery markets
  • 9:40 THE ROLE OF DRUG DELIVERY TECHNOLOGY

    Dr Paul Gellert

    Dr Paul Gellert, Manager, Drug Delivery, AstraZeneca

  • Benefits to company and consumer
  • Meeting consumer requirements through precise product selection
  • Implications for the pharmaceutical industry
  • Implications to the drug delivery companies
  • A future of steep competition for commercial success?
  • 10:20 DIFFERENTIATED DRUG DELIVERY TECHNOLOGIES

    Dr Giovanni Sala

    Dr Giovanni Sala, Senior Director, Commercial Licensing, Elan Pharmaceutical Technologies

  • The way forward: Non-invasive delivery
  • Pump in patch system - MEDIPAD: Controlled parenteral delivery
  • A patient friendly format
  • Solving drug delivery obstacles
  • Meeting challenges of the future
  • Availability of oral administration of macromolecules for tomorrow?
  • 11:00 Morning Coffee

    11:20 FAST DISSOLVE: SOLVING THE ISSUES OF A NEW DRYG DELIVERY TECHNOLOGY

    Dr John Siebert

    Dr John Siebert, , CIMA Labs

  • It always sounds easier than it really is
  • Key technology issues to overcome
  • Key attitude issues to overcome
  • What really makes the difference
  • Can you ever be really successful
  • Its never easy
  • 12:00 ADAPTIVE AEROSOL DELIVERY (ADD™)

    Jonathan Rigby

    Jonathan Rigby, Business Development Manager, Europe & Japan, Profile Therapeutics

  • Problems and issues facing successful pulmonary drug delivery
  • Overview of developments in inhalation technology
  • Improving the interface between the patient, the medication and the device
  • Advantages of ADD technology
  • 12:40 Lunch

    13:40 ADVANCED INHALED TECHNOLOGY

    Dr Mark Parry-Billings

    Dr Mark Parry-Billings, Director, Research & Development, Innovata Biomed

  • The critical link between formulation and device
  • Examples from recent developments
  • Regulatory challenges
  • Dry powder inhalers: the future?
  • 14:20 DEVELOPMENT OF NOVEL BIOMEDICAL PRODUCTS

    Dr James Brown

    Dr James Brown, President & Chief Executive Officer, DURECT Corporation

  • Site specific delivery
  • Reducing toxicity
  • Ensuring dosing compliance
  • Pump technologies
  • Microencapsulation
  • Biodegradable gel technology
  • 15:00 IMPLANTABLE MICROCHIPS FOR DRUG DELIVERY

    Dr John Santini Jr

    Dr John Santini Jr, President & Chief Scientific Officer, MicroCHIPS

  • Creation of the first ever ‘Pharmacy on a Chip’
  • Fabricated using methods for making silicon computer chips
  • Delivery of multiple drugs from a single device
  • Complex drug release profiles
  • Successful demonstration of in vivo drug release
  • New therapies enabled by ‘smart’ microchip delivery systems
  • 15:40 Afternoon Tea

    16:00 NOVEL TABLET TECHNOLOGY

    Dr Anand Baichwal

    Dr Anand Baichwal, Chief Scientific Officer & Senior Vice President, Research & New Technology Development, Penwest

  • Two unique delivery technologies developed from the TIMERx® Oral Drug Delivery Platform
  • Overview of Gemine™ (dual drug delivery) and a new technology for chronotherapeutic delivery
  • Challenges associated with dual release and/or chronotherapeutic delivery
  • Mechanisms of dual drug release and chronotherapeutic drug release
  • Release profiles that are achievable and how they can benefit future medicines
  • Unique drug delivery options for therapeutic advantage
  • 16:30 INHALERS: SO MANY TYPES?

    Dr Alison Moore

    Dr Alison Moore, Clinical Development Manager, Inhaled Delivery Systems, GlaxoSmithKline

  • Asthma: the size of the problem
  • Enhancement of delivery systems
  • Inhaled medications & the inhalers through which medications are delivered
  • Enhancement of the therapeutic effect through drug delivery
  • Importance of the market: evaluating patient device preference
  • Tomorrows inhalers?
  • 17:00 DRUG DELIVERY IN CANCER

    Dr William Vincek

    Dr William Vincek, Vice President, Pharmaceutical & Chemical Development, Guilford Pharmaceuticals

  • Improving efficacy and safety through novel methods of delivery
  • Developing cancer drug delivery technology
  • Innovative methods for tumour targeting
  • Implications to the companies, the health sectors, and the patients
  • Anti cancer therapies of the future
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Bas de Leeuw

    Bas de Leeuw, Co-Chair Marketing Committee, Controlled Release Society

    9:10 THE NEW ROLE OF THE CONTROLLED RELEASE SOCIETY

    Bas de Leeuw

    Bas de Leeuw, Co-Chair Marketing Committee, Controlled Release Society

  • History of the Controlled Release Society
  • Position of academic research in drug delivery and related sciences
  • Multi-directional knowledge sharing and technology transfer
  • New initiatives of the Controlled Release Society
  • 9:40 POLYSIALIC ACIDS: POTENTIAL IN DRUG DELIVERY

    Prof Gregory Gregoriadis

    Prof Gregory Gregoriadis, Professor, School of Pharmacy, University of London & Founding Director & Chief Scientific Advisor, Lipoxen Technologies

  • Basic aspects of polysialic acids
  • PolyXen™: Technology for the polysialylation of drugs, peptides, proteins and liposomes
  • Improving the stability and circulation time of therapeutics after parenteral administration
  • Applications of PolyXen™ technology
  • Advantages of PolyXen™ technology over other approaches
  • The way forward?
  • 10:20 DELIVERY OF POORLY SOLUBLE COMPOUNDS

    Dr Dianne Thompson

    Dr Dianne Thompson, Senior Vice President, Research & Development, CyDex

  • The effects of solubility problems on drug development
  • Delays or lost opportunities
  • The range of technology options to address solubility issues
  • Microemulsions, Nanotechnology, Complexing Agents (Cyclodextrins)
  • Candidates and routes suitable for Cyclodextrin solubilization
  • Commercial reality of a new solublizing technology CAPTISOL®
  • 11:00 Morning Coffee

    11:20 PHARMACOKINETICS

    Dr Jiunn Lin

    Dr Jiunn Lin, Executive Director, Drug Metabolism, Merck

  • Structure and mechanism of P-Glycoprotein
  • Tissue distribution of P-Glycoprotein expression
  • Implications of intestinal absorption
  • Implications of brain uptake
  • Potential of P-Glycoprotein mediated interactions
  • 12:00 HUMAN ABSORPTION STUDIES

    Dr Ian Wilding

    Dr Ian Wilding, Chief Executive, Pharmaceutical Profiles

  • Absorption; what are the key issues?
  • Improving decision making
  • Evaluation of novel drug delivery strategies and systems
  • Man as the best model for man
  • 12:40 Lunch

    14:00 NASAL DELIVERY

    Prof Lisbeth Illum

    Prof Lisbeth Illum, Chief Scientist, West Pharmaceutical Services

  • Simple yet effective design systems
  • Mechanisms of the system
  • Obtaining maximum consumer convenience
  • Implication to the health sector
  • Major markets of the future
  • 14:40 LIQUID-ENCAPSULATION TECHNOLOGY FOR ORAL DELIVERY

    Bill Bowtle

    Bill Bowtle, Technical Director, MW Encap

  • Target applications
  • Formulation approaches using lipids and non-lipids
  • Gelatin and substitutes
  • Multiple-capsule formats
  • Manufacturing systems
  • 15:20 Afternoon Tea

    15:40 THE INCREASING DEMAND FOR LESS INVASIVE TECHNOLOGY

    Chris Holmes

    Chris Holmes, Principal, WCI

  • Potentials of drug delivery on drug effectiveness
  • Difficulties with device design
  • Forming alliances: better to be flexible?
  • Regulatory issues affecting drug delivery
  • Market potential in relation to design and therapeutic action
  • A new world of drug delivery?
  • 16:20 MARKETS IN THE DRUG DELIVERY TECHNOLOGY INDUSTRY

    Dr Fintan Walton

    Dr Fintan Walton, Chief Executive Officer, PharmaVentures

  • Industry drivers: oral, transdermal, injection, inhalation delivery
  • The challenges facing market participants
  • Potential patent infringement - a high priority issue
  • Identification of market and business opportunities
  • Corporate partnerships - do they pay off?
  • A detailed road map of the future of the industry
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.